Study of Intraventricular Cerliponase Alfa for CLN2 Disease
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
Background Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children. Methods In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with CLN2 disease who were between the ages of 3 and 16 years. Treatment was initiated at a dose of 30 mg, 100 mg, or 300 mg; all the patients then received the 300-mg dose for at least 96 weeks. The primary outcome was the time until a 2-point decline in the score on the motor and language domains of the CLN2 Clinical Rating Scale (which ranges from 0 to 6, with 0 representing no function and 3 representing normal function in each of the two domains), which was compared with the time until a 2-point decline in 42 historical controls. We also compared the rate of decline in the motor-language score between the two groups, using data from baseline to the last assessment with a score of more than 0, divided by the length of follow-up (in units of 48 weeks). Results Twenty-four patients were enrolled, 23 of whom constituted the efficacy population. The median time until a 2-point decline in the motor-language score was not reached for treated patients and was 345 days for historical controls. The mean (±SD) unadjusted rate of decline in the motor-language score per 48-week period…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Precision therapy using intracerebroventricular enzyme replacement with recombinant human tripeptidyl peptidase 1 slowed disease progression in one study 148 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [148]
Citations
Cites
Sleat, D. E., Donnelly, R. J., Lackland, H., Liu, C.-G., Sohar, I., Pullarkat, R. K., & Lobel, P. (1997) · Science · doi:10.1126/science.277.5333.1802 · Cited by 581
NCL diseases - clinical perspectives
Schulz, A., Kohlschütter, A., Mink, J., Simonati, A., & Williams, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.008 · Cited by 246
Self-citationSleat, D. E., Gin, R. M., Sohar, I., Wisniewski, K., Sklower-Brooks, S., Pullarkat, R. K., Palmer, D. N., Lerner, T. J., Boustany, R.-M., Uldall, P., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302427 · Cited by 178
Steinfeld, R., Heim, P., von Gregory, H., Meyer, K., Ullrich, K., Goebel, H. H., & Kohlschütter, A. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10660 · Cited by 178
Self-citationThe Genetic Spectrum of Human Neuronal Ceroid‐lipofuscinoses
Mole, S. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00500.x · Cited by 115
Neurological deterioration in late infantile neuronal ceroid lipofuscinosis
Worgall, S., Kekatpure, M. V., Heier, L., Ballon, D., Dyke, J. P., Shungu, D., Mao, X., Kosofsky, B., Kaplitt, M. G., Souweidane, M. M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267885.47092.40 · Cited by 112
Self-citationKatz, M. L., Coates, J. R., Sibigtroth, C. M., Taylor, J. D., Carpentier, M., Young, W. M., Wininger, F. A., Kennedy, D., Vuillemenot, B. R., & O'Neill, C. A. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23423 · Cited by 100
Kishnani, P. S., Dickson, P., Muldowney, L., Lee, J. J., Rosenberg, A. S., Abichandani, R., Bluestone, J. A., Burton, B. K., Dewey, M. C., Freitas, A., et al. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.11.001 · Cited by 95
Vuillemenot, B. R., Katz, M. L., Coates, J. R., Kennedy, D., Tiger, P. M. N., Kanazono, S., Lobel, P., Sohár, I., Xu, S., Cahayag, R., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.018 · Cited by 81
Vuillemenot, B. R., Kennedy, D., Cooper, J. D., Wong, A. M. S., Sri, S., Doeleman, T., Katz, M. L., Coates, J. R., Johnson, G. C., Reed, R. P., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.004 · Cited by 60
Research works printed but not linked: 1
- Mole SE, Williams RE, Goebe HH, eds. The neuronal ceroid lipofuscinoses (Batten disease). 2nd ed. Oxford, England: Oxford University Press, 2011.
Cited by
Items 301–400 of 498
Enzyme Replacement Therapy in CLN2-Associated Retinopathy
Priglinger, C., Courage, C., & Maier, E. M. (2025) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2528-7886 · Cited by 4
“Cerliponase alfa is administered as an intracerebroventricular infusion over several hours every 2 weeks using an Ommaya or Rickham device as described above [4].”
InfluentialChakrabarti, S., Chandra, S., Roy, A., Dasarathi, S., Kundu, M., & Pahan, K. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.025 · Cited by 4
“A recent study showed that enzyme augmentation therapy via intraventricular infusion of cerliponase alfa (recombinant human pro-TPP1) reduces the impairment of locomotor and language functions in children affected with CLN2 disease (19).”
BackgroundInfluentialRed flags for neuronal ceroid lipofuscinosis type 2 disease
Trivisano, M., & Specchio, N. (2019) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14389 · Cited by 4
“Symptomatic treatments are currently available for most NCLs, and enzyme replacement treatment (ERT) for CLN2 disease has been developed and approved for clinical use.(1) Considering the (often rapid) neurodegenerative progression, early detection is important to gain the best results from treatment.”
BackgroundSelf-citationAtiskova, Y., Kohlschütter, A., Spitzer, M. S., & Dulz, S. (2020) · Der Ophthalmologe · doi:10.1007/s00347-020-01282-4 · Cited by 5
Self-citationRigaudière, F., Nasser, H., Pichard, S., Delouvrier, E., Lopez‐Hernandez, E., Milani, P., Auvin, S., & Delanöe, C. (2021) · Documenta Ophthalmologica · doi:10.1007/s10633-021-09825-z · Cited by 4
“However, complications such as infections or dysfunction of the intracerebroventricularly system have been reported [17].”
BackgroundAberrant splicing and transcriptional activity of TPP1 result in CLN2-like disorder
Helman, G., Taylor, L. E., Walkiewicz, M., Moing, M. L., Eggers, S., Yaplito‐Lee, J., Fuller, M., Dabscheck, G., Rodriguez‐Casero, V., White, S. M., et al. (2021) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2021.104259 · Cited by 4
Gutić, M., Milosavljević, M. N., Safiye, T., Milidrag, A., & Јаnkovic, S. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2197213 · Cited by 6
“The efficacy of cerliponase alfa was established in an open-label multicenter study in which cerliponase alfa demonstrated fewer declines in motor-language function compared with untreated patients in the natural cohort history [10].”
BackgroundCreating rare epilepsy cohorts using keyword search in electronic health records
Barbour, K. K., Tian, N., Yozawitz, E. G., Wolf, S. M., McGoldrick, P. E., Sands, T. T., Nelson, A. L. A., Basma, N., & Grinspan, Z. M. (2023) · Epilepsia · doi:10.1111/epi.17725 · Cited by 4
Boustany, R. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00467-2 · Cited by 4
Adams, H., Defendorf, S., Vierhile, A., Mink, J. W., Marshall, F. J., & Augustine, E. F. (2019) · Clinical Trials · doi:10.1177/1740774519855715 · Cited by 4
Lysosomal enzyme tripeptidyl peptidase 1 plays a role in degradation of beta amyloid fibrilsPreprint
Cruz, D. L., El-Banna, M., Majumdar, A., Sleat, D. E., Muldowney, M. T., Lobel, P., & Maxfield, F. (2019) · bioRxiv · doi:10.1101/639682 · Cited by 3
“Deficiency of TPP1 results in late infantile neuronal ceroid lipofuscinosis (LINCL), a childhood neurodegenerative lysosomal storage disease (Sleat et al., 1997).”
BackgroundEthical Issues in Care and Treatment of Neuronal Ceroid Lipofuscinoses (NCL)–A Personal View
Kohlschütter, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.692527 · Cited by 3
“While enzyme replacement therapy for CLN2 disease effectively slows neurological progression, there are no long-term results yet (15).”
BackgroundSelf-citationMatsushima, S. K., Shimada, Y., Kinoshita, M., Nagashima, T., Okamoto, S., Iizuka, S., Takagi, H., Iizuka, S., Higuchi, T., Hioki, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci180724 · Cited by 3
Fote, G., Schafenacker, A. M., Singh, J., Sherlock, D., Romero, B., Himstead, A. S., Davies, J. L., Pedroza, S., So, J., Gornick, W. B., et al. (2025) · Journal of Neurosurgery Pediatrics · doi:10.3171/2025.4.peds24452 · Cited by 3
Auvin, S., Hamandjian, M.-A., Karam, P., & Hoebeke, C. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.12.001 · Cited by 3
Gopalka, M., Patel, J., Votoupal, M., & Lam, S. K. (2026) · Children · doi:10.3390/children13030365 · Cited by 3
“Although effective, head-sited VAD access requires precise needle placement and may be challenging to maintain during prolonged infusions lasting several hours [10,11].”
Bartsch, S., Liu, J., Bassal, M., Jankowiak, W., Spitzer, M. S., & Bartsch, U. (2020) · Der Ophthalmologe · doi:10.1007/s00347-020-01237-9 · Cited by 3
The Neuronal Ceroid Lipofuscinoses
Mole, S. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197549469.003.0050 · Cited by 5
Inherited metabolic epilepsies–established diseases, new approaches
Latzer, I. T., & Pearl, P. L. (2024) · Epilepsia Open · doi:10.1002/epi4.13121 · Cited by 3
“57 Another therapeutic modality employed for LSDs is substrate reduction, which does not degrade the macro-molecules but slows their accumulation.”
Embracing the future: Neonatal screening for epileptic syndromes
Nabbout, R., & Kuchenbuch, M. (2025) · Epilepsia · doi:10.1111/epi.18285 · Cited by 3
“17 The replacement therapy with early recombinant human tripeptidyl peptidase introduction, has shown significant improvement in the survival and other outcomes in individuals with neuronal ceroid lipofuscinosis type 2 (CLN2), 18,19 a neurodegenerative lethal disease in early infancy.”
GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease mice
Takahashi, K., Rensing, N. R., Eultgen, E. M., Williams, L. L., Wang, S. H., Nelvagal, H. R., Le, S. Q., Roberts, M. S., Doray, B., Han, E. B., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.184487 · Cited by 3
“Although cerliponase alfa, an FDA-approved disease-modifying enzyme replacement therapy (ERT), now exists (17), this treatment only slows but fails to halt disease progression (18, 19).”
Gavin, M., Khatoon, S., Marchi, E. J., Mevs, C., Bolton, D. C., Velinov, M. T., & Junaid, M. A. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.04.010 · Cited by 3
Präzisionsmedizin in der Kinderneurologie am Beispiel der neuen Therapien
Ziegler, A. (2022) · Der Nervenarzt · doi:10.1007/s00115-021-01251-5 · Cited by 5
“satztherapieder spätinfantilenneuronalen Ceroid-LipofuszinoseTyp IImitCerliponase Alfa (Brineura), deren Wirksamkeit erfolgreich nachgewiesen werden konnte [32].”
BackgroundTherapies for Lysosomal Storage Diseases
Desnick, R. J., Astrin, K. H., & Schuchman, E. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812536-6.00007-9 · Cited by 4
Nott, E., Behl, K. E., Brambilla, I., Green, T. E., Lucente, M., Vavassori, R., Watson, A., Bernardina, B. D., & Hildebrand, M. S. (2023) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2022.104680 · Cited by 3
Specchio, N., Gissen, P., Reyes, E. D. L., Olaye, A., Camp, C., Curteis, T., Griffiths, A., Butt, T., Cohen-Pfeffer, J. L., Slasor, P., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302382 · Cited by 3
Self-citationHuang, W. C., Ohnsman, C. M., Atiskova, Y., Falabella, P., Spitzer, M. S., Schulz, A., & Dulz, S. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.8.45 · Cited by 3
“11,12 This study sought to further characterize the progression of CLN2 -associated retinopathy using OCT anatomical biomarkers, particularly those associated with vision loss despite receiving intraventricular cerliponase alfa therapy.”
BackgroundSelf-citationNatural history data for childhood neurodegenerative disease
Mink, J. W. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30210-4 · Cited by 3
Fetal gene therapy for neurodegenerative lysosomal storage diseases
Baruteau, J., & Waddington, S. N. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12018 · Cited by 3
Wibbeler, E., Wang, R., Reyes, E. D. L., Specchio, N., Gissen, P., Guelbert, N. B., Nickel, M., Schwering, C., Lehwald, L. M., Trivisano, M., et al. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.11.430 · Cited by 3
Self-citationБелоусова, Е. Д., & Sharkov, A. A. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201911911234 · Cited by 4
Wilton-Clark, H., Yan, E., & Yokota, T. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4730-1_4 · Cited by 3
Sharaireh, A. M., Guevara‐Ferrer, M., Ludlaim, A. M., Humphries, J. D., Phillips, A. M., Dowsey, A. W., Zhang, Z., Counsell, J. R., Unwin, R. D., Mole, S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08063-4 · Cited by 2
“IGF2R, also known as the calcium independent mannose-6-phosphate receptor (CI-M6PR), transports lysosomal enzymes to the lysosome from the Golgi network [34], as well as being an active plasma membrane transporter in enzyme replacement therapies [3, 35].”
Mortensen, A., Raebel, E. M., & Wiseman, S. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02147-y · Cited by 2
“A study in 24 children aged 3–16 years with CLN2 disease reported that treatment with cerliponase alfa significantly slowed decline in motor and language function compared with historic controls over 121 weeks’ treatment [8].”
MethodBarry, L. A., Kay, G. W., Mitchell, N. L., Murray, S. J., Jay, N. P., & Palmer, D. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261544 · Cited by 2
Intravitreal Injections in the Ovine Eye
Murray, S. J., & Mitchell, N. L. (2022) · Journal of Visualized Experiments · doi:10.3791/63823 · Cited by 3
An Optimized Comparative Proteomic Approach as a Tool in Neurodegenerative Disease Research
Kline, R. A., Lößlein, L., Kurian, D., Martí, J. A., Eaton, S. L., Court, F. A., Gillingwater, T. H., & Wishart, T. M. (2022) · Cells · doi:10.3390/cells11172653 · Cited by 3
Khamis, S., Mitakidou, M. R., Champion, M., Goyal, S., Jones, R. L., Siddiqui, A. U., Sabanathan, S., Hedderly, T. J., Lin, J., Jungbluth, H., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201385 · Cited by 2
Experimental pharmacology: Targeting metabolic pathways
Leuzzi, V., & Galosi, S. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.05.005 · Cited by 2
Protein–Protein Interactions in Neurodegenerative Diseases
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_3 · Cited by 5
Steigerwald, C. G., Borsuk, J., Pappas, J., Galey, M., Scott, A. I., Devaney, J. M., Miller, D. E., & Abreu, N. J. (2023) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2023.107713 · Cited by 2
Kiefer, M., Simione, M., Eichler, F., & Townsend, E. L. (2024) · Journal of Child Neurology · doi:10.1177/08830738241246703 · Cited by 2
“12-15 Currently, no validated disease-speci fi c clinical outcome assessment indexing health-related function exists for infantile GM2.”
BackgroundDue, C., Quinn, J., Gissen, P., Schulz, A., Specchio, N., Reyes, E. D. L., & Butt, T. (2024) · Healthcare · doi:10.3390/healthcare12222229 · Cited by 2
“…lipofuscinoses [LINCL] Scale) and 6-point Clinical Rating Scale ML (6-point scale including Motor and Language domains of the Adapted Clinical Rating Scale), and the parent/caregiver-reported Pediatric Quality of Life Inventory (PedsQL TM ) [11,15] and CLN2 Quality of Life (QoL) questionnaires.”
InfluentialSelf-citationTherapy for Neuropathic Lysosomal Storage Diseases
Zia, F., Khawaja, A. M., Bolanos, J. F., Morris, K., Heiss, J. D., & Kateb, B. (2024) · Springer eBooks · doi:10.1007/978-3-030-80662-0_17 · Cited by 2
The use of nanocarriers in treating Batten disease: A systematic review
Henke, L., Ghorbani, A., & Mole, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125094 · Cited by 4
“Notably, Brineura, which treats neuronal ceroid lipofuscinosis type 2 (CLN2) disease by delivering the recombinant TPP1 enzyme directly into the brain is now in the clinic (Schulz et al., 2024; Schulz et al., 2018).”
Magnetic Resonance Imaging as a Readout of CLN5 Gene Therapy Efficacy in Sheep
Murray, S. J., Almuqbel, M. M., Felton, S. A., Palmer, N. J., Deane, A. R., Myall, D. J., Shoorangiz, R., Ella, A., Keller, M., Palmer, D. N., et al. (2025) · Brain and Behavior · doi:10.1002/brb3.70431 · Cited by 2
“Currently, the only approved disease-modifying therapeutic for NCL is an enzyme replacement therapy for CLN2 disease; however, there are several promising candidate therapies currently in clinical trials for several forms of NCL (Liu et al. 2020; Schulz et al. 2018, 2024).”
Simonati, A., Pezzini, F., Nardocci, N., & Santorelli, F. M. (2025) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.16416 · Cited by 2
Ophthalmologic symptoms and diagnosis of a patient with Jansky-Bielschowsky disease
Modrzejewska, M., Kirkiewicz, M., Kiszkielis, A., & Lubiński, W. (2020) · Klinika Oczna · doi:10.5114/ko.2020.94210 · Cited by 2
“Introduction of cerliponase alpha significantly slows progression of the disease in terms of motor functions and speech disorders in children with CLN2, as demonstrated in phase I/II trials [12-14].”
BackgroundGuelbert, N. B., Atanacio, N. G., Denzler, I. M., Embiruçu, E. K., Mancilla, N., Flórez, R. A. N., Pessoa, A. L. S., Spécola, N. B., Tavera-Saldaña, L. M., Troncoso, M., et al. (2020) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1590/2326-4594-jiems-2020-0012 · Cited by 2
A Case Report on the Challenging Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
Nunes, A. F. P., Meira, J. G. C., Cunha, C., Veiga, M., de Magalhães, A. P. S., Málaga, D. R., Giugliani, R., & Leão, E. K. E. D. A. (2020) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1590/2326-4594-jiems-2020-0010 · Cited by 3
“This can be evaluated by the CLN2 Clinical Rating Scale, a score on the motor and language domains ranging from 0 to 6, with 0 representing no function and 3 representing normal function in each of the two domains [22].”
BackgroundMethod“Atypical” Phenotypes of Neuronal Ceroid Lipofuscinosis: The Argentine Experience in the Genomic Era
Pesaola, F. N., Guelbert, G., Venier, A. C., Cismondi, I. A., Becerra, A., Vázquez, J. C., Fernández, E. A., Paul, A. L. D., Guelbert, N. B., & de Halac, I. N. (2021) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1590/2326-4594-jiems-2021-0009 · Cited by 3
Herbal Bioactives for the Treatment of Idiopathic Pulmonary Fibrosis
Sharma, M., Garg, V., & Singh, I. (2021) · Springer eBooks · doi:10.1007/978-981-33-6850-7_15 · Cited by 2
Schwering, C., Apostolidou, S., Deindl, P., Christner, M., Knobloch, J. K. ‐., Herrmann, J., Kobbe, R., Schulz, A., Singer, D., & Ebenebe, C. U. (2022) · Neuropediatrics · doi:10.1055/s-0042-1750729 · Cited by 2
Self-citationChimeric cohorts and consortia can power and scale precision medicine
Silva, P. J., & Sweitzer, N. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00060-5 · Cited by 2
Neuronal Ceroid Lipofuscinoses
Vermilion, J. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00259-1 · Cited by 2
Neuronale Ceroid-Lipofuszinosen
Spitzer, M. S., & Bartsch, U. (2021) · Der Ophthalmologe · doi:10.1007/s00347-020-01304-1 · Cited by 2
Neuronal ceroid lipofuscinosis
St-Amant, M., Campos, A., & Sharma, R. (2016) · Radiopaedia.org · doi:10.53347/rid-48476 · Cited by 2
Sharaireh, A. M., Guevara‐Ferrer, M., Herranz-Martín, S., Macia, M. G., Phillips, A. M., Tierney, A. L., Hughes, M. P., Coombe-Tennant, O., Nelvagel, H., Burrows, A. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.21.488782 · Cited by 2
“At least four are soluble lysosomal enzymes (CLN1/PPT1, CLN2/TPP1, CLN5, CLN10/CTSD) 64 and Cerliponase alfa has proven to be a safe and efficacious enzyme replacement therapy in CLN2 Phase 65 I/II clinical trials (3).”
BackgroundJansen, M. J., Williams, L. L., Wang, S. H., Eultgen, E. M., Takahashi, K., Nelvagal, H. R., Sharma, J., Sardiello, M., DeBosch, B. J., Anderson, J. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.26.542524 · Cited by 2
Schneider, J., Mitschke, J., Bhat, M., Vogele, D., Schilling, O., Reinheckel, T., & Heß, L. (2024) · Biochimie · doi:10.1016/j.biochi.2024.03.013 · Cited by 1
Olkhovych, N. V., Pichkur, N., Mytsyk, N., Tonin, R., Kormoz, S., Hregul, I., Samonenko, N., Shkliarska, T., Olkhovych, V., Buryak, O., et al. (2024) · JIMD Reports · doi:10.1002/jmd2.12423 · Cited by 1
“12 Our work aimed to identify pathological variants in the TPP1 gene that conditioned the development of CLN2 disease in Ukrainian patients, to compare these variants with those found in patients from other European and non-European regions and to make genotype – phenotype associations for this…”
BackgroundAdvances in Gene Therapy for CLN2 (Batten) Disease
De, B. P., Rosenberg, J. B., Leopold, P. L., Kaminsky, S. M., Sondhi, D., & Crystal, R. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_9 · Cited by 1
Bryzik, A., Larysz, D., Larysz, P., Karpierz, J. I., & Paprocka, J. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1622185 · Cited by 1
Austin, G. L., Wang, F., Le, S. Q., Sorensen, A., Li, S., Foong, L. C., Singamsetty, S., Wood, J., Chou, T., & Dickson, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328941 · Cited by 1
“This study utilized ICV injections through an implanted catheter to deliver ERT to the CNS. ICV is safe in humans and mice and is an effective way to get therapy into the CNS [7,8,39].”
Biglari, S., Rezaei, H., Asadollahzadeh, E., Nikuei, P., Sahraian, M. A., Moghaddam, A. S., Vahidnezhad, H., Youssefian, L., Galehdari, H., Seifi, T., et al. (2026) · Human Genetics · doi:10.1007/s00439-025-02812-3 · Cited by 1
“The administration of cerliponase alfa directly intraventricular has proven to reduce CLN2 Clinical Rating Scale deterioration, mainly in motor and language areas, when compared to untreated historical controls (Schulz et al. 2018).”
Whiteley, R., Keating, M., McSweeney, M., Dorman, M., Antonini, M., Batzios, S. P., Footitt, E. J., Lee, L., & Gissen, P. (2026) · Biologics · doi:10.3390/biologics6010007 · Cited by 1
“Our findings nonetheless align with clinical trial and extension data for cerliponase alfa, demonstrating frequent but largely non-serious hypersensitivity events and rare anaphylaxis [8,10].”
InfluentialSelf-citationAdvances in Therapeutics—Enzyme Replacement Therapy: Long‐Term Evaluation and New Approaches
Lachmann, R. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70166 · Cited by 1
“ERT for neuronal ceroid lipofuscinosis type 2 (CLN2) is delivered by injection into a subcutaneous reservoir which has a catheter leading directly to the cerebral lateral ventricle [34].”
(2026) · Russian Journal of Child Neurology · doi:10.17650/2073-8803-2026-21-1-81-85 · Cited by 1
Petersen, M., Westermann, L. M., Hagenah, L., Nickel, M., Schwering, C., Wibbeler, E., Naegele, F. L., Gloyer, N.-O., Flottmann, F., Fiehler, J., et al. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70202 · Cited by 2
“For the Hamburg LINCL scale, only the motor and language domain performance (Hamburg ML scale) was included in the sum score, which aligns with previous studies employing them as primary outcome measures [7, 8].”
InfluentialSelf-citationNeurodegenerative Erkrankungen des Kindesalters
Schulz, A., & Nickel, M. (2018) · Medizinische Genetik · doi:10.1007/s11825-018-0194-2 · Cited by 1
Self-citationAnticonvulsant Agents: Beginning and Duration of Therapy, Withdrawal, and Resistance – Children
Borggraefe, I. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_371-1 · Cited by 1
Novel Treatments and Clinical Research in Child Neurology
Clark, G., & Lotze, T. E. (2021) · Neurologic Clinics · doi:10.1016/j.ncl.2021.05.004 · Cited by 1
New Drug: Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease
(2019) · Australian Prescriber · doi:10.18773/austprescr.2019.029 · Cited by 1
Neuroprotection in Neurodegenerative Disorders
Jain, K. K. (2019) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4939-9465-6_6 · Cited by 1
Visual perception and macular integrity in non-classical CLN2 disease
Atiskova, Y., Wildner, J., Wibbeler, E., Nickel, M., Spitzer, M. S., Schwering, C., Schulz, A., & Dulz, S. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05662-1 · Cited by 1
Self-citationGrabowski, G. A., & Hughes, D. A. (2022) · Wiley eBooks · doi:10.1002/9781119697312.ch26 · Cited by 1
[Application of adeno-associated virus-mediated gene therapy in lysosomal storage diseases].
Lin, X., Wang, X., & Peng, J. (2022) · PubMed · doi:10.7499/j.issn.1008-8830.2207055 · Cited by 1
Dem-Aging: autophagy-related pathologies and the “two faces of dementia”
Gammaldi, N., Doccini, S., Bernardi, S., Marchese, M., Cecchini, M. G., Ceravolo, R., Rapposelli, S., Ratto, G., Rocchiccioli, S., Pezzini, F., et al. (2023) · Neurogenetics · doi:10.1007/s10048-023-00739-3 · Cited by 1
“Therapies are merely palliative, and there is no cure for any form of NCL, although a slowing of the progressive course has been observed in a cohort of CLN2 patients undergoing enzyme replacement [4].”
Gkalapis, N., Dulz, S., Grohmann, C., Nickel, M., Schwering, C., Wibbeler, E., Spitzer, M. S., Schulz, A., & Atiskova, Y. (2024) · Eye and Brain · doi:10.2147/eb.s473408 · Cited by 1
“9 However, the progression of retinal degeneration has only been mitigated through preclinical treatment strategies that target the retina directly.”
Self-citationTay, S. K. H., & Pastores, G. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00063-9 · Cited by 1
Precision Medicine in the 21st Century: The Personalized Approach to Rare Neurologic Disease
Reyes, E. D. L. (2021) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2021.100883 · Cited by 1
Le, S. Q., Kan, S., Roberts, M. S., Dearborn, J. T., Wang, F., Li, S., Snella, E. M., Jens, J. K., Valentine, B. N., Nelvagal, H. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.06.455469 · Cited by 2
“In 59 the clinic, soluble lysosomal hydrolases are available in recombinant form for some types of 60 lysosomal storage disease, and may be delivered by repeated infusion into the bloodstream or 61 into the cerebrospinal fluid (3-9).”
The Neuronal Ceroid Lipofuscinoses
Scarpa, M., Bellettato, C. M., & Sechi, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-67727-5_61 · Cited by 1
Exploring the potential of natural history studies for rare neurological diseases
Muili, A. O., Gomez, A., Sulaiman, A. O., Mutata, S., Akhunji, M. T., Teemer, A., Shahzad, A., & Kuol, P. P. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002363 · Cited by 1
“The study ’ s natural history data served as a control for evaluating the use of intracerebroventricular replacement therapy with Intraventricular Cerliponase Alfa for CLN2 Disease, as conducted by Schulz et al. [6] .”
MethodLANGUAGE DEVELOPMENT DISORDERS
Prpić, I. (2020) · Paediatria Croatica · doi:10.13112/pc.401 · Cited by 1
Prenatal Diagnosis of Disorders of Lipid Metabolism
Humphries, S. E., Mole, S., & WINCHESTER, B. G. (2015) · Wiley eBooks · doi:10.1002/9781118981559.ch20
Fine, E. J., Langan, E., Lohr, L. A., & Mages, K. C. (2018) · Journal of the History of the Neurosciences · doi:10.1080/0964704x.2018.1527975
Lysosomale Speicherkrankheiten im Erwachsenenalter
Stulnig, T. M. (2019) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-018-0053-4
Development, Implementation, and Use of a Neurology Therapeutics Committee
Clark, E. B., Butterfield, R. J., Filloux, F. M., & Bonkowsky, J. L. (2019) · Child Neurology Open · doi:10.1177/2329048x19830473
Neurodegenerative Erkrankungen der grauen Hirnsubstanz
Kohlschütter, A. (2020) · Springer Reference Medizin · doi:10.1007/978-3-662-60300-0_254
Self-citationFortschritte in der Therapie von neurometabolischen Erkrankungen
Decker, C., & Lücke, T. (2019) · Pädiatrie · doi:10.1007/s15014-019-1742-1
“Erstmals wurde 2017 mit Cerliponase alfa eine Enzymersatztherapie zugelassen, die zweiwöchentlich direkt intrathekal verabreicht wird und die in Phase-I/II-Studien einen signi©kanten E ekt bezüglich der Verlangsamung des motorischen und sprachlichen Abbaus gezeigt hat [14].”
BackgroundNelvagal, H. R., & Cooper, J. D. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1703672
“There are currently no curative therapies for any form of NCL, although a disease-stabilizing therapy is now available for CLN2 disease [1,5,6].”
BackgroundIntrathecal enzyme replacement therapy for CLN2 disease
Kohlschütter, A. (2019) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2019-8-4-29-32
Self-citationBatten Disease - Beyond the Blind Spots
Kuper, W. F. E. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/225
Bartsch, U., Liu, J., Bassal, M., Jankowiak, W., Spitzer, M. S., & Bartsch, S. (2021) · Der Ophthalmologe · doi:10.1007/s00347-021-01419-z
“Daten aus mehreren präklinischen Studien und einer kürzlich publizierten klinischen Studie an CLN2-Patienten [9] zeigten, dass die Netzhaut trotz der beeindruckenden Ergebnisse am Gehirn von solchen spezifisch auf das Gehirn ausgerichteten Therapieansätzen nicht profitiert.”
BackgroundPrecision medicine for epilepsies: are we there yet?
Andrade, D. M. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326697
Kick, G. R. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/88127
Lightning progress in child neurology in the past 20 years
Scheffer, I. E. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00002-3
Coppieters, F., Héon, E., & Grudzinska Pechhacker, M. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-813944-8.00035-4
Prenatal Diagnosis of Disorders of Lipid Metabolism
Davison, J. E., Humphries, S. E., WINCHESTER, B. G., & Mole, S. (2021) · Wiley eBooks · doi:10.1002/9781119676980.ch25
Metadata
- Authors
- Schulz, A., Ajayi, T., Specchio, N., de Los Reyes, E., Gissen, P., Ballon, D., Dyke, J. P., Cahan, H., Slasor, P., Jacoby, D., & Kohlschütter, A.
- Affiliations
- Nationwide Children's Hospital (US)
- From the Department of Pediatrics, University Medical Center Hamburg–Eppendorf, Hamburg, Germany (A.S., A.K.); BioMarin Pharmaceutical, Novato, CA (T.A., H.C., P.S., D.J.); the Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome (N.S.); Nationwide Children’s Hospital and Ohio State University, Columbus (E.L.R.); UCL Great Ormond Street Institute of Child Health, London (P.G.); and the Citigroup Biomedical Imaging Center, Departments of Radiology and Genetic Medicine, Weill...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-17
- Volume
- 378
- Issue
- 20
- Pages
- 1898-1907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2799850385
- Cited by
- 489
- References
- 17
- Citations by year
- 2026: 36 · 2025: 57 · 2024: 37 · 2023: 49 · 2022: 86 · 2021: 74 · 2020: 83 · 2019: 47 · 2018: 17
- FWCI
- 37.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health Research
- European Union Seventh Framework Program Grand (281234)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- cerliponase alfa, CLN2 disease, neuronal ceroid lipofuscinosis type 2, intraventricular infusion, enzyme replacement therapy, tripeptidyl peptidase 1, lysosomal storage disease, pediatric patients, device-related infection, adverse events
- MeSH terms
- Tripeptidyl-Peptidase 1, Adolescent, Child, Child, Preschool, Dementia, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Female, Humans, Language Development, Male, Motor Skills, Neuronal Ceroid-Lipofuscinoses, Recombinant Proteins, Disease Progression, Kaplan-Meier Estimate, Enzyme Replacement Therapy, Infusions, Intraventricular, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.